PCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pacira Biosciences Inc (PCRX) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 to invest. The technical indicators show a bearish trend, options data suggests weak sentiment, and there are no recent positive news or financial catalysts. Analysts' ratings are mixed, with some optimism for long-term growth but limited near-term momentum. Given the lack of strong buy signals and the negative price trend, it is advisable to hold off on purchasing this stock at the moment.
The MACD is negatively expanding, RSI is at 29.143 (neutral), and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels indicate the stock is trading near its lower support levels (S2: 21.907). Overall, the technical indicators suggest a bearish trend.
Hedge funds are increasing their buying activity significantly (695.83% increase). Analysts from Needham and H.C. Wainwright maintain Buy ratings with price targets of $32 and $38, respectively, citing growth potential and reduced opioid usage from Exparel.
Insiders are selling heavily (636.27% increase in selling). Barclays lowered its price target to $25, citing limited near-term momentum. The stock has a 70% chance of declining further in the short term (-4.35% in the next week).
No financial data available for analysis.
Analysts are mixed. Needham and H.C. Wainwright are optimistic with Buy ratings and higher price targets, while Barclays remains cautious with an Equal Weight rating and a reduced price target of $25.
